8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(D) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of earliest event reported): February 5, 2007

                         Renhuang Pharmaceuticals, Inc.
             (Exact name of registrant as specified in its charter)

                                     Nevada
                 (State or Other Jurisdiction of Incorporation)


                  0-24512                       88-1273503
          (Commission File Number) (IRS Employer Identification Number)

                    No. 281, Taiping Road, Taiping District,
                      Harbin, Heilongjiang Province, 150050
                                   P. R. China
                    (Address of Principal Executive Offices)

                                +86-451-5762-0378
              (Registrant's Telephone Number, Including Area Code)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_| Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))


- --------------------------------------------------------------------------------







Item 7.01   Regulation FD Disclosure.
            -------------------------

 On February 5, 2007, Renhuang Pharmaceuticals, Inc (the "Company") issued a
press release, a copy of which is attached as Exhibit 99.1 to this report and
is being furnished to the SEC and shall not be deemed "filed" for any purpose.



Item 9.01   Financial Statements, Pro Form Financial Information and Exhibits.
(c)         Exhibits.


                                    EXHIBITS

Exhibit                           Description
- -------                           ----------------------------------------------
99.1                              Press Release dated February 5, 2007.


- --------------------------------------------------------------------------------









                                   SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                    Renhuang Pharmaceuticals, Inc.


Date: February 5, 2007              By: /s/ Shaoming Li
                                        ----------------------------------------
                                        Shaoming Li
                                        Chief Executive Officer and President


- --------------------------------------------------------------------------------

EX-99.1

                                                                    Exhibit 99.1

   Renhuang's New Ginseng Ointment Product Receives Great Interest
               at Recent Promotional Meetings in China


    HARBIN, China--(BUSINESS WIRE)--Feb. 5, 2007--Renhuang
Pharmaceuticals, Inc. (or "the Company", Stock symbol: RHGP.OB), a
leading provider of natural health care products in the People's
Republic of China (PRC), recently held new product promotion meetings
in Xinjiang province and Sichuan province separately to introduce and
showcase the Company's newly launched product - Ginseng Ointment. A
total of more than 200 people representing pharmaceutical companies
and distributors from the two provinces, independent local sales
agents and contractors, representatives from the media and advertising
agencies attended the events. As a new product with both
bio-nutritional and bio-pharmaceutical value, Ginseng Ointment
received great interest from the meeting participants. Renhuang
believes that the interest showed at the meetings is likely to result
in a significant amount of purchasing orders shortly.

    The Company launched Ginseng Ointment recently in early December,
2006 after it had been approved by the State Food and Drug
Administration, P.R. China (SFDA). The complex formula developed
in-house is based on an ancient Chinese medical tradition and consists
of effective components from Ginseng and various herbal plants and
animals. The health benefits of this bio-medicine include enhancing
energy and blood circulation, improving metabolism and the immune
system, and also helping improve liver and kidney function.

    This product is a direct result of the Company's Research &
Development efforts, broadens the company's offering in
bio-pharmaceutical products, and complements Renhuang's main Siberian
Ginseng product line. The main target group is men and women between
the ages of 20 and 50 with higher than average income. The Company
estimates that sales of the new product could reach $10 million
dollars in 2007 with a projected net profit of $5 million dollars.

    About Renhuang Pharmaceuticals, Inc.:

    Renhuang Pharmaceuticals is a leading bio-pharmaceutical company
located in Harbin in the Heilongjiang Province in Northeast China.
Renhuang is primarily engaged in the research, production, and sales
of bio-pharmaceutical products in Mainland China. The Company's main
products are Siberian ginseng, shark liver oil and several other
traditional medical products. It is estimated that 70% of China's
natural supply of Siberian Ginseng is currently controlled by the
Company.

    The company also anticipates approval within six to nine months by
State Food and Drug Administration ("SFDA") for up to five of its new
Monoclonal Antibody Reagent Box series products. These products are
60% more reliable than those from its competitors and also adhere to
"Good Manufacturing Practices", or "GMP". Moreover, the company is in
the process of building its own immune system research and development
function. Overall, the company is able to achieve significant cost
savings compared to most of its competitors, who purchase their raw
materials from third parties.

    Over 2000 sales agents are employed in seventy sales centers
across twenty-four districts and cover over 50% of the greater China
area and 80% of its population, including the most populous and
developed Eastern China. The Company employs over 50 people in its R&D
department, a number of which are well recognized and respected
pharmaceutical professors and research scientists from National Navy
Pharmaceutical Research Center, Beijing Ellionbio Research Center and
other well known institutions. State of the art research and
production facilities using the latest technologies are currently used
by the Company's scientists to develop new and innovative areas,
including antiseptic and immune system products and Diagnostic kits.
RHGP-G

    Safe Harbor Statement

    This press release contains certain statements that may include
'forward-looking statements' as defined in the Securities Act of 1933,
and the Securities Exchange Act of 1934. All statements, other than
statements of historical facts, included herein are 'forward-looking
statements.' Although the Company believes that the expectations
reflected in these forward-looking statements are reasonable, they do
involve assumptions, risks and uncertainties, and these expectations
may prove to be incorrect. You should not place undue reliance on
these forward-looking statements, which speak only as of the date of
this press release.

    The Company's actual results could differ materially from those
anticipated in these forward-looking statements as a result of a
variety of factors, including those discussed in the Company's
periodic reports that are filed with and available from the Securities
and Exchange Commission. All forward-looking statements attributable
to the Company or persons acting on its behalf are expressly qualified
in their entirety by these factors. Other than as required under the
securities laws, the Company does not assume a duty to update these
forward-looking statements.


    CONTACT: Christensen
             Tip Fleming, 917-412-3333
             tfleming@christensenir.com
             or
             In China:
             Renhuang Pharmaceuticals Inc
             Gina Gao, 0086-451-57620378
             Fax: 0086-451-57606414
             gs@renhuang.com